{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:33:39Z","timestamp":1773038019949,"version":"3.50.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>The use of immune checkpoint inhibitors (ICIs) in melanoma patients has significantly improved treatment outcomes. Unfortunately, ICI therapy is associated with specific immune-related adverse events (irAEs). There is limited data on the use of ICIs in patients with autoimmune or allergic diseases, because these patients have typically been excluded from clinical trials. Eosinophilic inflammatory bowel disease (primary eosinophilic gastrointestinal disorders) is a rare condition defined as eosinophilic infiltration in the wall of the gastrointestinal tract in the absence of other known causes of tissue eosinophilia. We present a case of a 51-year-old woman with eosinophilic enteritis who was treated with anti-PD-1 because of metastatic melanoma. The use of anti-PD-1 therapy in a metastatic melanoma patient with a positive history of eosinophilic enteritis resulted in the appearance of many immune-related complications (hypothyroidism, hepatitis, skin lesions, colitis). The patient discontinued anti-PD-1 treatment and glucocorticoid therapy was started. All AEs have resolved without any sequelae, and there are no symptoms of eosinophilic enteritis. Currently, the patient has no complaints, and has no clinical features of recurrence or dissemination of melanoma (April 2020); she remains under constant oncological supervision. The use of anti-PD-1 therapy in a patient with metastatic melanoma and a positive history of eosinophilic enteritis resulted in almost complete remission of melanoma but also the appearance of many immune-related complications, none of which were life-threatening. Patients with eosinophilic enteritis may be eligible for anti-PD-1 therapy; however, they should be closely monitored for the appearance of various irAEs when receiving this therapy.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000693","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T06:01:47Z","timestamp":1597730507000},"page":"619-624","source":"Crossref","is-referenced-by-count":5,"title":["Immune-related adverse events in a patient with eosinophilic enteritis treated with immune checkpoint inhibitors (anti-PD-1)"],"prefix":"10.1097","volume":"30","author":[{"given":"Bo\u017cena","family":"Cybulska-Stopa","sequence":"first","affiliation":[{"name":"Clinical Oncology Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gra\u017cyna","family":"Kami\u0144ska-Winciorek","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Dyduch","sequence":"additional","affiliation":[{"name":"Department of Pathomorphology, Jagiellonian University Medical College, Cracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"R1-20230902","first-page":"105","article-title":"Eosinophilic gastrointestinal disorders.","volume":"4","author":"Rogowska","year":"2012","journal-title":"Gastroenterologia Kliniczna"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11894-018-0645-6","article-title":"Diagnosis, natural history and treatment of eosinophilic enteritis: a review.","volume":"20","author":"Pineton de Chambrun","year":"2018","journal-title":"Curr Gastroenterol Rep"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3748\/wjg.v13.i11.1758","article-title":"Eosinophilic gastroenteritis presenting as small bowel obstruction: a case report and review of the literature.","volume":"13","author":"Yun","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study.","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","article-title":"Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors.","volume":"17","author":"Kennedy","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl_4","key":"R7-20230902","first-page":"iv119","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"28","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"1722022","DOI":"10.1080\/2162402X.2020.1722022","article-title":"Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database.","volume":"9","author":"Scanvion","year":"2020","journal-title":"Oncoimmunology"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s40425-019-0743-5","article-title":"Dual checkpoint inhibitor-associated eosinophilic enteritis.","volume":"7","author":"Yang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/01.COT.0000532231.52108.7f","article-title":"Nivolumab dosing schedule approved for every 4 weeks.","volume":"40","year":"2018","journal-title":"Oncology Times"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-018-2255-4","article-title":"Opposing roles of eosinophils in cancer.","volume":"68","author":"Simon","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/ni.3159","article-title":"Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.","volume":"16","author":"Carretero","year":"2015","journal-title":"Nat Immunol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T04:06:49Z","timestamp":1693627609000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000693","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,17]]}}}